[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @3primeAnalytica 3PrimeAnalytica 3PrimeAnalytica posts on X about $regn, collab, vivo, investment the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1372950951175278595/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Year XXXXXXX +7,528% ### Mentions: X [#](/creator/twitter::1372950951175278595/posts_active)  - X Week XX -XX% - X Month XX +5.80% - X Year XXX +3,038% ### Followers: XXXXX [#](/creator/twitter::1372950951175278595/followers)  - X Week XXXXX -XXXX% - X Month XXXXX +2.80% - X Year XXXXX +50% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1372950951175278595/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XX% [technology brands](/list/technology-brands) XXXXX% [cryptocurrencies](/list/cryptocurrencies) XXXXX% **Social topic influence** [$regn](/topic/$regn) #19, [collab](/topic/collab) 16.67%, [vivo](/topic/vivo) 16.67%, [investment](/topic/investment) 16.67%, [regeneron](/topic/regeneron) #18, [$beam](/topic/$beam) 16.67%, [ind](/topic/ind) 8.33%, [$regns](/topic/$regns) 8.33%, [$13bn](/topic/$13bn) 8.33%, [the worlds](/topic/the-worlds) XXXX% **Top accounts mentioned or mentioned by** [@phucthinhbtv](/creator/undefined) [@jessiechimni](/creator/undefined) [@regeneron](/creator/undefined) [@elikorey](/creator/undefined) [@aditharun_](/creator/undefined) [@nejm](/creator/undefined) [@geneinvesting](/creator/undefined) [@drfager](/creator/undefined) [@s_gallagher23](/creator/undefined) [@alexfabra339670](/creator/undefined) [@yhdjdhd](/creator/undefined) [@ny1972_47](/creator/undefined) **Top assets mentioned** [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [BEAM (BEAM)](/topic/$beam) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) ### Top Social Posts Top posts by engagements in the last XX hours "🚨 $REGN and Tessera Therapeutics have announced collab to develop TSRA-196 Tesseras lead in vivo Gene Writing candidate for AATD. Deal terms: -$150 M upfront (cash + equity investment) -Up to $XXX M in near- and mid-term R&D milestones -50/50 global cost- and profit-sharing -IND filing expected by end of 2025" [X Link](https://x.com/3primeAnalytica/status/1995519768921575465) 2025-12-01T15:46Z 1384 followers, 5897 engagements "This marks $REGN's 5th major platform-level commitment to next-gen genetic medicines in just X years - a deliberate disciplined strategy that has now seen the company deploy $1.3bn in upfront cash and equity across the most promising technologies in the space. This is a systematic build-out of a complete genetic medicines toolkit backed by the worlds best human genetics engine.the RGC (Regeneron Genetics Center). ✅2016 $NTLA $125m (CRISPR) ✅2019 $ALNY $800m (RNAi) ✅2023 Decibel $109m (AAV GT) ✅2024 Mammoth $XX (CRISPR) ✅2025 Tessera $150m (GW) 👆If you think George and Len just dropped $150m" [X Link](https://x.com/3primeAnalytica/status/1995536691403063413) 2025-12-01T16:53Z 1384 followers, 4644 engagements "$REGN back $XXX Fireside chats at Wolfe Research & Jefferies conferences a few days ago ☕ @Regeneron highlighted solid growth & pipeline momentum at Q3 earnings call (up XX% since). These chats revealed fresh details on onco catalysts Eylea HD trajectory obesity strategy & some other 💎. Still one of my top LT picks. Izzy Lowy (Onc Head) Justin Holko (Onc Commercial) Chris Fenimore (CFO) delivered these updates. 🔬 Onco Pipe: High Confidence in Fianlimab + Libtayo Combo; Serious Player Status Cemented 📍 Lowy with strong optimism for PD-1/LAG-3 combo in adv. melanoma with P3 PFS readout now" [X Link](https://x.com/3primeAnalytica/status/1991218151909101769) 2025-11-19T18:52Z 1384 followers, 1063 engagements "$REGN Fireside Chat at Evercore ISI Key Takeaways ☕ Marion (CCO) + Crowe (EVP R&D) as usual delivered a very confident detailed and fwd-looking discussion today. Clear pride in a highly productive 2025 across com. execution pipe dev. and capital allocation & with firm conviction for 2026. Tone was the usual consistently upbeat zero defensiveness - pure Regeneron execution mode. 📍 2025 highlights from Marion - EYLEA HD continued strong share gains + newly launched Q4w dosing & RVO indication (RVO 1718% of legacy EYLEA business XX% of total anti-VEGF market) - Dupi now X indications in US" [X Link](https://x.com/3primeAnalytica/status/1996008383002914993) 2025-12-03T00:07Z 1384 followers, 1092 engagements "🚨 Regulatory Tailwinds for Gene Editing Companies Regulatory advancements are emerging globally potentially benefiting the gene-editing sector by streamlining approval processes reducing evidentiary requirements and introducing expedited pathways. Companies such as $CRSP $NTLA $BEAM $SANA and $CRBU stand to gain significantly. This post outlines key developments. If you know of others please share in the replies. FDA's Conditional Approval Pathway for Rare Diseases Announced in April 2025 - This mechanism enables conditional approvals based on plausible biological mechanisms for ultra-rare" [X Link](https://x.com/3primeAnalytica/status/1960044067728859237) 2025-08-25T18:18Z 1382 followers, 3874 engagements "@EliKorey @GeneInvesting yes and they first need to see if they are even allowed to pursue AATD anyway" [X Link](https://x.com/3primeAnalytica/status/1995596941225566380) 2025-12-01T20:52Z 1382 followers, XX engagements "🚨 $BEAM BEACON update looksoutstanding. -With XX pts treated (data cutoff Aug. X 2025) and follow-up extending to 20.4m the dataset's maturity has advanced meaningfully. -Core bio and clinical signals remain not just consistent but solid vs. prior readoutsno attenuation of fetal haemoglobin (HbF) no new safety concerns and XXX% severe VOC-free post-engraftment. ✅editing rates XXXX% at month XXXXX% at month XX ✅Mean HbF sustained XX% with highly pancell distribution (95% F-cells typically carrying protective levels) ✅HbS durably XX% (mean 3035%). ✅Total Hb rapid rise to normal ranges;" [X Link](https://x.com/3primeAnalytica/status/1997350822762434779) 2025-12-06T17:01Z 1382 followers, 2197 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@3primeAnalytica 3PrimeAnalytica
3PrimeAnalytica posts on X about $regn, collab, vivo, investment the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Year XXXXXXX +7,528%
Mentions: X #
- X Week XX -XX%
- X Month XX +5.80%
- X Year XXX +3,038%
Followers: XXXXX #
- X Week XXXXX -XXXX%
- X Month XXXXX +2.80%
- X Year XXXXX +50%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXXXX% finance XX% technology brands XXXXX% cryptocurrencies XXXXX%
Social topic influence $regn #19, collab 16.67%, vivo 16.67%, investment 16.67%, regeneron #18, $beam 16.67%, ind 8.33%, $regns 8.33%, $13bn 8.33%, the worlds XXXX%
Top accounts mentioned or mentioned by @phucthinhbtv @jessiechimni @regeneron @elikorey @aditharun_ @nejm @geneinvesting @drfager @s_gallagher23 @alexfabra339670 @yhdjdhd @ny1972_47
Top assets mentioned Regeneron Pharmaceuticals Inc (REGN) BEAM (BEAM) CRISPR Therapeutics AG (CRSP) Intellia Therapeutics, Inc (NTLA)
Top Social Posts
Top posts by engagements in the last XX hours
"🚨 $REGN and Tessera Therapeutics have announced collab to develop TSRA-196 Tesseras lead in vivo Gene Writing candidate for AATD. Deal terms: -$150 M upfront (cash + equity investment) -Up to $XXX M in near- and mid-term R&D milestones -50/50 global cost- and profit-sharing -IND filing expected by end of 2025"
X Link 2025-12-01T15:46Z 1384 followers, 5897 engagements
"This marks $REGN's 5th major platform-level commitment to next-gen genetic medicines in just X years - a deliberate disciplined strategy that has now seen the company deploy $1.3bn in upfront cash and equity across the most promising technologies in the space. This is a systematic build-out of a complete genetic medicines toolkit backed by the worlds best human genetics engine.the RGC (Regeneron Genetics Center). ✅2016 $NTLA $125m (CRISPR) ✅2019 $ALNY $800m (RNAi) ✅2023 Decibel $109m (AAV GT) ✅2024 Mammoth $XX (CRISPR) ✅2025 Tessera $150m (GW) 👆If you think George and Len just dropped $150m"
X Link 2025-12-01T16:53Z 1384 followers, 4644 engagements
"$REGN back $XXX Fireside chats at Wolfe Research & Jefferies conferences a few days ago ☕ @Regeneron highlighted solid growth & pipeline momentum at Q3 earnings call (up XX% since). These chats revealed fresh details on onco catalysts Eylea HD trajectory obesity strategy & some other 💎. Still one of my top LT picks. Izzy Lowy (Onc Head) Justin Holko (Onc Commercial) Chris Fenimore (CFO) delivered these updates. 🔬 Onco Pipe: High Confidence in Fianlimab + Libtayo Combo; Serious Player Status Cemented 📍 Lowy with strong optimism for PD-1/LAG-3 combo in adv. melanoma with P3 PFS readout now"
X Link 2025-11-19T18:52Z 1384 followers, 1063 engagements
"$REGN Fireside Chat at Evercore ISI Key Takeaways ☕ Marion (CCO) + Crowe (EVP R&D) as usual delivered a very confident detailed and fwd-looking discussion today. Clear pride in a highly productive 2025 across com. execution pipe dev. and capital allocation & with firm conviction for 2026. Tone was the usual consistently upbeat zero defensiveness - pure Regeneron execution mode. 📍 2025 highlights from Marion - EYLEA HD continued strong share gains + newly launched Q4w dosing & RVO indication (RVO 1718% of legacy EYLEA business XX% of total anti-VEGF market) - Dupi now X indications in US"
X Link 2025-12-03T00:07Z 1384 followers, 1092 engagements
"🚨 Regulatory Tailwinds for Gene Editing Companies Regulatory advancements are emerging globally potentially benefiting the gene-editing sector by streamlining approval processes reducing evidentiary requirements and introducing expedited pathways. Companies such as $CRSP $NTLA $BEAM $SANA and $CRBU stand to gain significantly. This post outlines key developments. If you know of others please share in the replies. FDA's Conditional Approval Pathway for Rare Diseases Announced in April 2025 - This mechanism enables conditional approvals based on plausible biological mechanisms for ultra-rare"
X Link 2025-08-25T18:18Z 1382 followers, 3874 engagements
"@EliKorey @GeneInvesting yes and they first need to see if they are even allowed to pursue AATD anyway"
X Link 2025-12-01T20:52Z 1382 followers, XX engagements
"🚨 $BEAM BEACON update looksoutstanding. -With XX pts treated (data cutoff Aug. X 2025) and follow-up extending to 20.4m the dataset's maturity has advanced meaningfully. -Core bio and clinical signals remain not just consistent but solid vs. prior readoutsno attenuation of fetal haemoglobin (HbF) no new safety concerns and XXX% severe VOC-free post-engraftment. ✅editing rates XXXX% at month XXXXX% at month XX ✅Mean HbF sustained XX% with highly pancell distribution (95% F-cells typically carrying protective levels) ✅HbS durably XX% (mean 3035%). ✅Total Hb rapid rise to normal ranges;"
X Link 2025-12-06T17:01Z 1382 followers, 2197 engagements